Browse Studies — Arctuva

Phase 3

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in…

Acute Promyelocytic Leukemia (APL)Acute Promyelocytic LeukaemiaAcute Promyelocytic Leukemia With PML-RARA+2 more

Estimated

~$10 – $8,750

Quetzal TherapeuticsNCT07504458

Phase 2

Phase II Study of Treatment of Acute Promyelocytic Leukemia (APL) With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin (GO)

This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated …

Acute Promyelocytic Leukemia With PML-RARA

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT01409161

Phase 1

PET/MR, PET/CT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)

This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomo…

Acute Myeloid LeukemiaAcute Promyelocytic Leukemia With PML-RARA

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT02390635